$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 23 Nov 2016 | 20614 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.Influenza A Virus, H5N1 Subtype Infections.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 6

    List of Figures 7

    Introduction 8

    Global Markets Direct Report Coverage 8

    Influenza A Virus, H5N1 Subtype Infections Overview 9

    Therapeutics Development 10

    Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Overview 10

    Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Comparative Analysis 11

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Development by Companies 12

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15

    Influenza A Virus, H5N1 Subtype Infections - Pipeline Products Glance 16

    Late Stage Products 16

    Clinical Stage Products 17

    Early Stage Products 18

    Influenza A Virus, H5N1 Subtype Infections - Products under Development by Companies 19

    Influenza A Virus, H5N1 Subtype Infections - Products under Investigation by Universities/Institutes 23

    Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 24

    Akshaya Bio Inc 24

    Altimmune Inc 25

    Antigen Express Inc 26

    Aphios Corp 27

    BioDiem Ltd 28

    BiondVax Pharmaceuticals Ltd 29

    CEL-SCI Corp 30

    Cocrystal Pharma Inc 31

    Emergent BioSolutions Inc 32

    Gemmus Pharma Inc 33

    GlaxoSmithKline Plc 34

    Hemispherx Biopharma Inc 35

    iBio Inc 36

    Inovio Pharmaceuticals Inc 37

    Johnson & Johnson 38

    Kineta Inc 39

    Lakewood-Amedex Inc 40

    Medicago Inc 41

    Medigen Vaccine Biologics Corp. 42

    Microbiotix Inc 43

    NanoBio Corp 44

    Nanotherapeutics Inc 45

    NanoViricides Inc 46

    NewLink Genetics Corp 47

    OPKO Health Inc 48

    PaxVax Inc 49

    PeptiDream Inc 50

    Protein Sciences Corp 51

    Shionogi & Co Ltd 52

    Takeda Pharmaceutical Company Ltd 53

    TechnoVax Inc 54

    TGV-Laboratories 55

    Vaxart Inc 56

    Vaxine Pty Ltd 57

    VaxInnate Corp 58

    Visterra Inc 59

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 60

    Assessment by Monotherapy Products 60

    Assessment by Combination Products 61

    Assessment by Target 62

    Assessment by Mechanism of Action 64

    Assessment by Route of Administration 66

    Assessment by Molecule Type 68

    Drug Profiles 70

    A-06 - Drug Profile 70

    AE-443p - Drug Profile 71

    Alferon LDO - Drug Profile 72

    APP-0205 - Drug Profile 74

    APP-309 - Drug Profile 75

    AT-301 - Drug Profile 76

    CEL-1000 - Drug Profile 77

    CHOS-05 - Drug Profile 79

    DPC-005 - Drug Profile 80

    FBF-001 - Drug Profile 81

    Gamma-Flu - Drug Profile 82

    GP-1001 - Drug Profile 83

    GP-1002 - Drug Profile 84

    GP-1681 - Drug Profile 85

    GREFLU/VIE - Drug Profile 87

    HAI-05 - Drug Profile 88

    HB-36.6 - Drug Profile 89

    Influ-nRNA - Drug Profile 90

    influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 91

    influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile 92

    influenza [strain A/H5N1] vaccine - Drug Profile 95

    influenza [strain A/H5N1] vaccine - Drug Profile 96

    influenza [strain A/H5N1] vaccine - Drug Profile 97

    influenza [strain A/H5N1] vaccine - Drug Profile 99

    influenza [strain A/H5N1] vaccine - Drug Profile 100

    influenza [strain A/H5N1] vaccine - Drug Profile 101

    influenza [strain A/H5N1] vaccine - Drug Profile 102

    influenza [strain A/H5N1] vaccine - Drug Profile 103

    influenza [strain A/H5N1] vaccine - Drug Profile 104

    influenza [strain A/H5N1] vaccine 2 - Drug Profile 105

    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 106

    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 107

    influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 108

    influenza [strains A/H5N1 + A/H7N2 + A/H9N2] (virus like particle) vaccine - Drug Profile 109

    influenza vaccine - Drug Profile 110

    INO-3510 - Drug Profile 111

    JNJ-872 - Drug Profile 113

    KD-295 - Drug Profile 115

    KIN-1148 - Drug Profile 116

    Lalistat - Drug Profile 117

    M-001 - Drug Profile 118

    MBX-2329 - Drug Profile 123

    MBX-2546 - Drug Profile 124

    Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile 125

    MV-4 - Drug Profile 126

    MVAH-5HA - Drug Profile 127

    Nasovax - Drug Profile 128

    NVINF-1 - Drug Profile 130

    NVINF-2 - Drug Profile 134

    OrniFlu - Drug Profile 137

    PanBlok - Drug Profile 138

    PD-001 - Drug Profile 141

    PNSIA-28 - Drug Profile 142

    PNSIA-49 - Drug Profile 143

    PXVX-0103 - Drug Profile 144

    rintatolimod - Drug Profile 145

    S-033188 - Drug Profile 154

    Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 156

    Small Molecules to Activate Sirtuin for Influenza - Drug Profile 157

    Small Molecules to Inhibit PB2 for Influenza - Drug Profile 158

    Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 159

    Synthetic Peptides for Viral Infections - Drug Profile 160

    TVX-003 - Drug Profile 161

    VAX-161C - Drug Profile 162

    VGX-3400X - Drug Profile 163

    VH-244 - Drug Profile 164

    VIS-410 - Drug Profile 165

    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 168

    Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 174

    Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 175

    Featured News & Press Releases 175

    Appendix 185

    Methodology 185

    Coverage 185

    Secondary Research 185

    Primary Research 185

    Expert Panel Validation 185

    Contact Us 185

    Disclaimer 186

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

20614 | GMDHC8695IDB

Number of Pages

191

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Influenza Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Influenza B Infections Global Clinical Trials Review, H1, 2016
Influenza B Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,500 More Info
Pandemic Influenza Global Clinical Trials Review, H1, 2016
Pandemic Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report,...
20 Jan 2016 by Global Data USD $2,500 More Info
Influenza A Infections Global Clinical Trials Review, H1, 2016
Influenza A Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,500 More Info
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical...
20 Jan 2016 by Global Data USD $2,500 More Info
Swine Influenza Global Clinical Trials Review, H1, 2016
Swine Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “S...
20 Jan 2016 by Global Data USD $2,500 More Info
Seasonal Influenza Global Clinical Trials Review, H2, 2015
Seasonal Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,500 More Info
Influenza A Infections Global Clinical Trials Review, H2, 2015
Influenza A Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,500 More Info
Pandemic Influenza Global Clinical Trials Review, H2, 2015
Pandemic Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,500 More Info
Influenza B Infections Global Clinical Trials Review, H2, 2015
Influenza B Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...